Found 1 matching record:
HXB2 Location | Gag(77-85) | Gag Epitope Map
View variants at this location |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epitope |
SLYNTVATL
|
Epitope Alignment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variants |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epitope Name | SL9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Species (MHC/HLA) | human(A*02:01) |
Showing all: 151 variant(s).
Variant ID. | 4507 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYNTVAvL |
Mutations | R/L T/V |
Epitope Location | R-1L T8V |
HXB2 Location | R76L T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNTVAvL (-1 to the start of epitope SL9) had an increase in replicative capacity but did not have an increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4508 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYNTVATL |
Mutations | R/L |
Epitope Location | R-1L |
HXB2 Location | R76L |
Mutation Type | SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CTL suppression of replication, Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNTVATL (-1 to the start of epitope SL9) only had an increased replicative capacity when cultured without SLYNTVATL-specific CTL clones and elicited an in vitro CTL response. |
Variant ID. | 4509 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {m}SLYNTVATL |
Mutations | R/M |
Epitope Location | R-1M |
HXB2 Location | R76M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, mSLYNTVATL (-1 to the start of epitope SL9) only had an increased replicative capacity when cultured without CTLs. |
Variant ID. | 4510 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNaVAvL |
Mutations | T/A T/V |
Epitope Location | T5A T8V |
HXB2 Location | T81A T84V |
Mutation Type | NSF: non-susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CTL suppression of replication, Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNaVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, and an increase in replicative capacity. SLYNaVAvL has escape mutant potential as defined by authors which was confirmed by the absence of a SLYNaVAvL-specific CTL response in vitro. |
Variant ID. | 4511 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {m}SLYNTVAvL |
Mutations | R/M T/V |
Epitope Location | R-1M T8V |
HXB2 Location | R76M T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, mSLYNTVAvL (-1 to the start of epitope SL9) had an increased replicative capacity but only had at least a 2-fold increase in relative enrichment when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones vs. without CTLs. |
Variant ID. | 4512 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {i}SLYNTVATL |
Mutations | R/I |
Epitope Location | R-1I |
HXB2 Location | R76I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, iSLYNTVATL (-1 to the start of epitope SL9) had a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones but an increased replicative capacity when cultured without CTLs. |
Variant ID. | 4513 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | aLYNTVAvL |
Mutations | S/A T/V |
Epitope Location | S1A T8V |
HXB2 Location | S77A T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aLYNTVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones vs. without CTLs. aLYNTVAvL has escape mutant potential as defined by authors. |
Variant ID. | 4514 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | aLfNTVATL |
Mutations | S/A Y/F |
Epitope Location | S1A Y3F |
HXB2 Location | S77A Y79F |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | When cultured with each of 3 SLYNTVATL-specific CTL clones, aLfNTVATL had at least a 10-fold, a 5-fold and a 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. |
Variant ID. | 4515 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNiVATL |
Mutations | T/I |
Epitope Location | T5I |
HXB2 Location | T81I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNiVATL had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4516 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {q}SLYNTVAvL |
Mutations | R/Q T/V |
Epitope Location | R-1Q T8V |
HXB2 Location | R76Q T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, qSLYNTVAvL (-1 to the start of epitope SL9) had an increased replicative capacity, but only had a 10-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4517 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {q}SLYNTVATL |
Mutations | R/Q |
Epitope Location | R-1Q |
HXB2 Location | R76Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, qSLYNTVATL (-1 to the start of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4518 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYNTVATL |
Mutations | R/V |
Epitope Location | R-1V |
HXB2 Location | R76V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVATL (-1 to the start of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4519 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNcVATL |
Mutations | T/C |
Epitope Location | T5C |
HXB2 Location | T81C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNcVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors. |
Variant ID. | 4520 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {t}SLYNTVATL |
Mutations | R/T |
Epitope Location | R-1T |
HXB2 Location | R76T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, tSLYNTVATL (-1 to the start of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4521 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTiAsL |
Mutations | V/I T/S |
Epitope Location | V6I T8S |
HXB2 Location | V82I T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTiAsL had an increased replicative capacity when cultured without CTLs and a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4522 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNsVAvL |
Mutations | T/S T/V |
Epitope Location | T5S T8V |
HXB2 Location | T81S T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to B clade consensus variant, SLYNsVAvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNsVAvL also had an increased replicative capacity. As defined by the authors, SLYNsVAvL has escape mutant potential. |
Variant ID. | 4523 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNciATL |
Mutations | T/C V/I |
Epitope Location | T5C V6I |
HXB2 Location | T81C V82I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNciATL had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, as well as increased replicative capacity. As defined by authors, this suggests that SLYNciATL has escape mutant potential. |
Variant ID. | 4524 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | aLYNTVATL |
Mutations | S/A |
Epitope Location | S1A |
HXB2 Location | S77A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aLYNTVATL had at least a 2-fold to 5-fold increase in relative enrichment when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4525 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVAvL |
Mutations | T/V |
Epitope Location | T8V |
HXB2 Location | T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by the authors, this suggests that SLYNTVAvL has escape mutant potential. |
Variant ID. | 4526 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNlVATL |
Mutations | T/L |
Epitope Location | T5L |
HXB2 Location | T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNlVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, and an increase in replicative capacity. As defined by authors, SLYNlVATL has escape mutant potential. |
Variant ID. | 4527 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {t}SLYNTVAvL |
Mutations | R/T T/V |
Epitope Location | R-1T T8V |
HXB2 Location | R76T T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, tSLYNTVAvL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by authors, this suggests that tSLYNTVAvL has escape mutant potential. |
Variant ID. | 4528 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYNTVAvL |
Mutations | R/V T/V |
Epitope Location | R-1V T8V |
HXB2 Location | R76V T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVAvL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with 2 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by authors, this suggests that vSLYNTVAvL has escape mutant potential. |
Variant ID. | 4529 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTiAvL |
Mutations | V/I T/V |
Epitope Location | V6I T8V |
HXB2 Location | V82I T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | When cultured with each of 3 SLYNTVATL-specific CTL clones, SLYNTiAvL had at least a 10-fold, 5-fold and 2-fold increase in relative enrichment vs. when cultured without CTLs, relative to consensus variant. |
Variant ID. | 4530 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYNlVATL |
Mutations | R/L T/L |
Epitope Location | R-1L T5L |
HXB2 Location | R76L T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNlVATL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4531 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {n}SLYNTVAvL |
Mutations | R/N T/V |
Epitope Location | R-1N T8V |
HXB2 Location | R76N T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, nSLYNTVAvL (-1 to the start of epitope SL9) had at least a 5-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4532 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {f}SLYNTVATL |
Mutations | R/F |
Epitope Location | R-1F |
HXB2 Location | R76F |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, fSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4533 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTiATL |
Mutations | V/I |
Epitope Location | V6I |
HXB2 Location | V82I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTiATL had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4534 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVAcL |
Mutations | T/C |
Epitope Location | T8C |
HXB2 Location | T84C |
Mutation Type | NSF: non-susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CTL suppression of replication, Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAcL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by the authors, SLYNTVAcL has escape mutant potential which was confirmed by the absence of a SLYNTVAcL-specific CTL response in vitro. |
Variant ID. | 4535 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYNTVAcL |
Mutations | R/L T/C |
Epitope Location | R-1L T8C |
HXB2 Location | R76L T84C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNTVAcL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4536 |
---|---|
Epitope Seq. | {R}SLYNTVATL{Y} |
Variant Seq. | {l}SLYNTVATL{w} |
Mutations | Y/W R/L |
Epitope Location | Y+1W R-1L |
HXB2 Location | Y86W R76L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNTVATLw (-1 and +1 residues flanking SL9 epitope) had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4537 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {c}SLYNTVATL |
Mutations | R/C |
Epitope Location | R-1C |
HXB2 Location | R76C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, cSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones. |
Variant ID. | 4538 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SLYNTVATL |
Mutations | R/K |
Epitope Location | R-1K |
HXB2 Location | R76K |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, kSLYNTVATL (-1 to the start of epitope SL9) had similar replicative capacity. |
Variant ID. | 4539 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNcVAcL |
Mutations | T/C T/C |
Epitope Location | T5C T8C |
HXB2 Location | T81C T84C |
Mutation Type | NSF: non-susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CTL suppression of replication, Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNcVAcL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNcVAcL has escape mutant potential as defined by authors which was confirmed by the absence of a SLYNcVAcL-specific CTL response in vitro. |
Variant ID. | 4540 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTcAvL |
Mutations | V/C T/V |
Epitope Location | V6C T8V |
HXB2 Location | V82C T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTcAvL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTcAvL only had moderately reduced replicative capacity, relative to B clade consensus variant. As defined by authors, SLYNTcAvL has escape mutant potential. |
Variant ID. | 4541 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVAsL |
Mutations | T/S |
Epitope Location | T8S |
HXB2 Location | T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors. |
Variant ID. | 4542 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLfNTVATL |
Mutations | Y/F |
Epitope Location | Y3F |
HXB2 Location | Y79F |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLfNTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors. |
Variant ID. | 4543 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNlVAvL |
Mutations | T/L T/V |
Epitope Location | T5L T8V |
HXB2 Location | T81L T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNlVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, and only moderately reduced replicative capacity. As defined by authors, SLYNlVAvL has escape mutant potential. |
Variant ID. | 4544 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVAaL |
Mutations | T/A |
Epitope Location | T8A |
HXB2 Location | T84A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAaL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors. |
Variant ID. | 4545 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {m}SLYNlVATL |
Mutations | R/M T/L |
Epitope Location | R-1M T5L |
HXB2 Location | R76M T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, mSLYNlVATL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. |
Variant ID. | 4546 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYNlVATL |
Mutations | R/V T/L |
Epitope Location | R-1V T5L |
HXB2 Location | R76V T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNlVATL (-1 to the start of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones. vSLYNlVATL also had a reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4547 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {h}SLYNTVATL |
Mutations | R/H |
Epitope Location | R-1H |
HXB2 Location | R76H |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, hSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity. |
Variant ID. | 4548 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {a}SLYNTVATL |
Mutations | R/A |
Epitope Location | R-1A |
HXB2 Location | R76A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity. |
Variant ID. | 4549 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{c} |
Mutations | Y/C |
Epitope Location | Y+1C |
HXB2 Location | Y86C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATLc (+1 to the end of epitope SL9) had a lower replicative capacity. |
Variant ID. | 4550 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{f} |
Mutations | Y/F |
Epitope Location | Y+1F |
HXB2 Location | Y86F |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATLf (+1 to the end of epitope SL9) had a lower replicative capacity. |
Variant ID. | 4551 |
---|---|
Epitope Seq. | {R}SLYNTVATL{Y} |
Variant Seq. | {v}SLYNTVATL{w} |
Mutations | Y/W R/V |
Epitope Location | Y+1W R-1V |
HXB2 Location | Y86W R76V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVATLw (-1 and +1 residues flanking SL9 epitope) had at least a 2-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vSLYNTVATLw also had a reduced replicative capacity, relative the B clade consensus variant. |
Variant ID. | 4552 |
---|---|
Epitope Seq. | {R}SLYNTVATL{Y} |
Variant Seq. | {m}SLYNTVATL{w} |
Mutations | Y/W R/M |
Epitope Location | Y+1W R-1M |
HXB2 Location | Y86W R76M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, mSLYNTVATLw (-1 and +1 residues flanking SL9 epitope) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had reduced replicative capacity. |
Variant ID. | 4553 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {w}SLYNTVATL |
Mutations | R/W |
Epitope Location | R-1W |
HXB2 Location | R76W |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, wSLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity. |
Variant ID. | 4554 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {s}SLYNTVATL |
Mutations | R/S |
Epitope Location | R-1S |
HXB2 Location | R76S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, sSLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity. |
Variant ID. | 4555 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {n}SLYNTVATL |
Mutations | R/N |
Epitope Location | R-1N |
HXB2 Location | R76N |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, nSLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity. |
Variant ID. | 4556 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {a}aLYNTVATL |
Mutations | R/A S/A |
Epitope Location | R-1A S1A |
HXB2 Location | R76A S77A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aaLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity. |
Variant ID. | 4557 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}aLYNTVATL |
Mutations | R/L S/A |
Epitope Location | R-1L S1A |
HXB2 Location | R76L S77A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, laLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity. |
Variant ID. | 4558 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYsTVATL |
Mutations | R/L N/S |
Epitope Location | R-1L N4S |
HXB2 Location | R76L N80S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYsTVATL (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity. |
Variant ID. | 4559 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {c}SLYNTVAvL |
Mutations | R/C T/V |
Epitope Location | R-1C T8V |
HXB2 Location | R76C T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, cSLYNTVAvL (-1 to the start of epitope SL9) had at least a 5-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had similar or lower replicative capacity. |
Variant ID. | 4560 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {s}SLYNTVAvL |
Mutations | R/S T/V |
Epitope Location | R-1S T8V |
HXB2 Location | R76S T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, sSLYNTVAvL (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had lower replicative capacity. |
Variant ID. | 4561 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYNTVAsL |
Mutations | R/V T/S |
Epitope Location | R-1V T8S |
HXB2 Location | R76V T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVAsL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4562 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYNTVAaL |
Mutations | R/L T/A |
Epitope Location | R-1L T8A |
HXB2 Location | R76L T84A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNTVAaL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4563 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYNTVAaL |
Mutations | R/V T/A |
Epitope Location | R-1V T8A |
HXB2 Location | R76V T84A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVAaL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4564 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAvL{w} |
Mutations | Y/W T/V |
Epitope Location | Y+1W T8V |
HXB2 Location | Y86W T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAvLw (+1 to the end of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4565 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAvL{s} |
Mutations | Y/S T/V |
Epitope Location | Y+1S T8V |
HXB2 Location | Y86S T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAvLs (+1 to the end of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4566 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAvL{r} |
Mutations | Y/R T/V |
Epitope Location | Y+1R T8V |
HXB2 Location | Y86R T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAvLr (+1 to the end of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVAvLr also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4567 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{w} |
Mutations | Y/W |
Epitope Location | Y+1W |
HXB2 Location | Y86W |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATLw (+1 to the end of epitope SL9) had at least a 5-fold increase in relative enrichment, when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4568 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVATm |
Mutations | L/M |
Epitope Location | L9M |
HXB2 Location | L85M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATm had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATm also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4569 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | aLYNTVAaL |
Mutations | S/A T/A |
Epitope Location | S1A T8A |
HXB2 Location | S77A T84A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aLYNTVAaL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. aLYNTVAaL also had reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4570 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | aLYNTVAsL |
Mutations | S/A T/S |
Epitope Location | S1A T8S |
HXB2 Location | S77A T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aLYNTVAsL had at least a 10-fold increase in relative enrichment when cultured with 3 SLYNTVATL-specific CTL clones vs. without CTLs. aLYNTVAsL also had reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4571 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNaVATL |
Mutations | T/A |
Epitope Location | T5A |
HXB2 Location | T81A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNaVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4572 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNsVATL |
Mutations | T/S |
Epitope Location | T5S |
HXB2 Location | T81S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNsVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4573 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNvVATL |
Mutations | T/V |
Epitope Location | T5V |
HXB2 Location | T81V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNvVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4574 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNrVATL |
Mutations | T/R |
Epitope Location | T5R |
HXB2 Location | T81R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNrVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs. |
Variant ID. | 4575 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNlVAsL |
Mutations | T/L T/S |
Epitope Location | T5L T8S |
HXB2 Location | T81L T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNlVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4576 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNvVAsL |
Mutations | T/V T/S |
Epitope Location | T5V T8S |
HXB2 Location | T81V T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNvVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4577 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | gLYNTVAvL |
Mutations | S/G T/V |
Epitope Location | S1G T8V |
HXB2 Location | S77G T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, gLYNTVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity. |
Variant ID. | 4578 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | cLYNTVAvL |
Mutations | S/C T/V |
Epitope Location | S1C T8V |
HXB2 Location | S77C T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, cLYNTVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4579 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | gLYNTVATL |
Mutations | S/G |
Epitope Location | S1G |
HXB2 Location | S77G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, gLYNTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4580 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | mLYNTVATL |
Mutations | S/M |
Epitope Location | S1M |
HXB2 Location | S77M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, mLYNTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4581 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYmTVATL |
Mutations | N/M |
Epitope Location | N4M |
HXB2 Location | N80M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYmTVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4582 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYrTVATL |
Mutations | N/R |
Epitope Location | N4R |
HXB2 Location | N80R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYrTVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4583 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYgTVAvL |
Mutations | N/G T/V |
Epitope Location | N4G T8V |
HXB2 Location | N80G T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYgTVAvL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when passaged without CTLs. |
Variant ID. | 4584 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYsTVAvL |
Mutations | N/S T/V |
Epitope Location | N4S T8V |
HXB2 Location | N80S T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYsTVAvL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when passaged without CTLs. |
Variant ID. | 4585 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYcTVAvL |
Mutations | N/C T/V |
Epitope Location | N4C T8V |
HXB2 Location | N80C T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYcTVAvL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4586 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYgTVAsL |
Mutations | N/G T/S |
Epitope Location | N4G T8S |
HXB2 Location | N80G T84S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYgTVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when passaged without CTLs. |
Variant ID. | 4587 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYgTVgTL |
Mutations | N/G A/G |
Epitope Location | N4G A7G |
HXB2 Location | N80G A83G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYgTVgTL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4588 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVgTL |
Mutations | A/G |
Epitope Location | A7G |
HXB2 Location | A83G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVgTL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4589 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVsTL |
Mutations | A/S |
Epitope Location | A7S |
HXB2 Location | A83S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVsTL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4590 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTcATL |
Mutations | V/C |
Epitope Location | V6C |
HXB2 Location | V82C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTcATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4591 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SiYNTVATL |
Mutations | L/I |
Epitope Location | L2I |
HXB2 Location | L78I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SiYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SiYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4592 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | StYNTVATL |
Mutations | L/T |
Epitope Location | L2T |
HXB2 Location | L78T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, StYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. StYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4593 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | ScYNTVATL |
Mutations | L/C |
Epitope Location | L2C |
HXB2 Location | L78C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, ScYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. ScYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4594 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SvYNTVATL |
Mutations | L/V |
Epitope Location | L2V |
HXB2 Location | L78V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | When cultured with each of 3 SLYNTVATL-specific CTL clones, SvYNTVATL had at least a 10-fold, 5-fold, and 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. SvYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4595 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | avYNTVATL |
Mutations | S/A L/V |
Epitope Location | S1A L2V |
HXB2 Location | S77A L78V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, avYNTVATL had at least a 2-fold to 10-fold increase in relative enrichment (RE) when cultured with each of 3 SLYNTVATL-specific CTL clones vs. without CTLs. avYNTVATL also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4596 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | vLYNTVATL |
Mutations | S/V |
Epitope Location | S1V |
HXB2 Location | S77V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | When cultured with each of 3 SLYNTVATL-specific CTL clones, vLYNTVATL had at least a 10-fold, 5-fold, and 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. vLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4597 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | tLYNTVATL |
Mutations | S/T |
Epitope Location | S1T |
HXB2 Location | S77T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, tLYNTVATL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. tLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4598 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | rLYNTVATL |
Mutations | S/R |
Epitope Location | S1R |
HXB2 Location | S77R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, rLYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. rLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4599 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | wLYNTVATL |
Mutations | S/W |
Epitope Location | S1W |
HXB2 Location | S77W |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, wLYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. wLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4600 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | qLYNTVATL |
Mutations | S/Q |
Epitope Location | S1Q |
HXB2 Location | S77Q |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, qLYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. qLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4601 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYyTVATL |
Mutations | N/Y |
Epitope Location | N4Y |
HXB2 Location | N80Y |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYyTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYyTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4602 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYvTVATL |
Mutations | N/V |
Epitope Location | N4V |
HXB2 Location | N80V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYvTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYvTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4603 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYfTVATL |
Mutations | N/F |
Epitope Location | N4F |
HXB2 Location | N80F |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYfTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYfTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4604 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYsTVATL |
Mutations | N/S |
Epitope Location | N4S |
HXB2 Location | N80S |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYsTVATL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYsTVATL also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4605 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYlTVATL |
Mutations | N/L |
Epitope Location | N4L |
HXB2 Location | N80L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYlTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYlTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4606 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYaTVATL |
Mutations | N/A |
Epitope Location | N4A |
HXB2 Location | N80A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYaTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYaTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4607 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYtTVATL |
Mutations | N/T |
Epitope Location | N4T |
HXB2 Location | N80T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYtTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYtTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4608 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYgaVATL |
Mutations | N/G T/A |
Epitope Location | N4G T5A |
HXB2 Location | N80G T81A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYgaVATL had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgaVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4609 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYyTVAvL |
Mutations | N/Y T/V |
Epitope Location | N4Y T8V |
HXB2 Location | N80Y T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYyTVAvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYyTVAvL also had a substantially reduced replicative capacity. |
Variant ID. | 4610 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYslVATL |
Mutations | N/S T/L |
Epitope Location | N4S T5L |
HXB2 Location | N80S T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to B clade consensus variant, SLYslVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4611 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNvlATL |
Mutations | T/V V/L |
Epitope Location | T5V V6L |
HXB2 Location | T81V V82L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNvlATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNvlATL also had a substantially reduced replicative capacity. |
Variant ID. | 4612 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTtATL |
Mutations | V/T |
Epitope Location | V6T |
HXB2 Location | V82T |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTtATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTtATL also had a substantially reduced replicative capacity. |
Variant ID. | 4613 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTlATL |
Mutations | V/L |
Epitope Location | V6L |
HXB2 Location | V82L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTlATL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTlATL also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4614 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVgvL |
Mutations | A/G T/V |
Epitope Location | A7G T8V |
HXB2 Location | A83G T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVgvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVgvL also had a substantially reduced replicative capacity. |
Variant ID. | 4615 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVAiL |
Mutations | T/I |
Epitope Location | T8I |
HXB2 Location | T84I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAiL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVAiL also had a substantially reduced replicative capacity. |
Variant ID. | 4616 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLrNTVATL |
Mutations | Y/R |
Epitope Location | Y3R |
HXB2 Location | Y79R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLrNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLrNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4617 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLvNTVATL |
Mutations | Y/V |
Epitope Location | Y3V |
HXB2 Location | Y79V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLvNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLvNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4618 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLwNTVATL |
Mutations | Y/W |
Epitope Location | Y3W |
HXB2 Location | Y79W |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLwNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLwNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4619 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVATv |
Mutations | L/V |
Epitope Location | L9V |
HXB2 Location | L85V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATv had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATv also had a substantially reduced replicative capacity. |
Variant ID. | 4620 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVATi |
Mutations | L/I |
Epitope Location | L9I |
HXB2 Location | L85I |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATi had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATi also had a substantially reduced replicative capacity. |
Variant ID. | 4621 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {y}SLYNTVATL |
Mutations | R/Y |
Epitope Location | R-1Y |
HXB2 Location | R76Y |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, ySLYNTVATL (-1 to the start of epitope SL9) had a substantially reduced replicative capacity. |
Variant ID. | 4622 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{l} |
Mutations | Y/L |
Epitope Location | Y+1L |
HXB2 Location | Y86L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATLl (+1 to the end of epitope SL9) had a substantially reduced replicative capacity. |
Variant ID. | 4623 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}SLYNvVATL |
Mutations | R/L T/V |
Epitope Location | R-1L T5V |
HXB2 Location | R76L T81V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, lSLYNvVATL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4624 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {c}SLYNlVATL |
Mutations | R/C T/L |
Epitope Location | R-1C T5L |
HXB2 Location | R76C T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, cSLYNlVATL (-1 to the start of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. cSLYNlVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4625 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {c}SLYNvVATL |
Mutations | R/C T/V |
Epitope Location | R-1C T5V |
HXB2 Location | R76C T81V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, cSLYNvVATL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but had a reduced replicative capacity. |
Variant ID. | 4626 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {g}SLYNTVATL |
Mutations | R/G |
Epitope Location | R-1G |
HXB2 Location | R76G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to the consensus variant, gSLYNTVATL (-1 to the start of epitope SL9) had a 2-fold to 5-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. gSLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4627 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {e}SLYNTVATL |
Mutations | R/E |
Epitope Location | R-1E |
HXB2 Location | R76E |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to the consensus variant, eSLYNTVATL (-1 to the start of epitope SL9) had a 2-fold to 5-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. eSLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4628 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {l}gLYNTVATL |
Mutations | R/L S/G |
Epitope Location | R-1L S1G |
HXB2 Location | R76L S77G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | When cultured with each of 3 SLYNTVATL-specific CTL clones, lgLYNTVATL (-1 to the start of epitope SL9) had at least a 10-fold, a 5-fold and a 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. lgLYNTVATL also had a reduced replicative capacity. |
Variant ID. | 4629 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAvL{l} |
Mutations | Y/L T/V |
Epitope Location | Y+1L T8V |
HXB2 Location | Y86L T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | When cultured with each of 3 SLYNTVATL-specific CTL clones, SLYNTVAvLl (+1 to the end of epitope SL9) had at least a 10-fold, a 5-fold and a 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. SLYNTVAvLl also had a substantially reduced replicative capacity. |
Variant ID. | 4630 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SvYNTVATL |
Mutations | R/K L/V |
Epitope Location | R-1K L2V |
HXB2 Location | R76K L78V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, kSvYNTVATL (-1 to the start of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. kSvYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4631 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}gLYNTVATL |
Mutations | R/V S/G |
Epitope Location | R-1V S1G |
HXB2 Location | R76V S77G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, vgLYNTVATL (-1 to the start of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vgLYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4632 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{a} |
Mutations | Y/A |
Epitope Location | Y+1A |
HXB2 Location | Y86A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to the consensus variant, SLYNTVATLa (+1 to the end of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment when cultured with 3 SLYNTVATL-specific CTL clones vs. when cultured without CTLs. SLYNTVATLa also had a substantially reduced replicative capacity. |
Variant ID. | 4633 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYaTVATL |
Mutations | R/V N/A |
Epitope Location | R-1V N4A |
HXB2 Location | R76V N80A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, vSLYaTVATL (-1 to the start of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vSLYaTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4634 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYgTVATL{m} |
Mutations | Y/M N/G |
Epitope Location | Y+1M N4G |
HXB2 Location | Y86M N80G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, SLYgTVATLm (+1 to the end of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgTVATLm also had a substantially reduced replicative capacity. |
Variant ID. | 4635 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAvL{a} |
Mutations | Y/A T/V |
Epitope Location | Y+1A T8V |
HXB2 Location | Y86A T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, SLYNTVAvLa (+1 to the end of epitope SL9) had a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVAvLa also had a substantially reduced replicative capacity. |
Variant ID. | 4636 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYgTVATL{a} |
Mutations | Y/A N/G |
Epitope Location | Y+1A N4G |
HXB2 Location | Y86A N80G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, SLYgTVATLa (+1 to the end of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgTVATLa also had a substantially reduced replicative capacity. |
Variant ID. | 4637 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNvVATL{w} |
Mutations | Y/W T/V |
Epitope Location | Y+1W T5V |
HXB2 Location | Y86W T81V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNvVATLw (+1 to the end of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNvVATLw also had a substantially reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4638 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | aLYNTVATL{l} |
Mutations | Y/L S/A |
Epitope Location | Y+1L S1A |
HXB2 Location | Y86L S77A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aLYNTVATLl (+1 to the end of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. aLYNTVATLl also had a substantially reduced replicative capacity. |
Variant ID. | 4639 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAcL{l} |
Mutations | Y/L T/C |
Epitope Location | Y+1L T8C |
HXB2 Location | Y86L T84C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAcLl (+1 to the end of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with SLYNTVATL-specific CTL clones vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4640 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{m} |
Mutations | Y/M |
Epitope Location | Y+1M |
HXB2 Location | Y86M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVATLm (+1 to the end of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATLm also had a substantially reduced replicative capacity. |
Variant ID. | 4641 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {a}SLYNTVAvL |
Mutations | R/A T/V |
Epitope Location | R-1A T8V |
HXB2 Location | R76A T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aSLYNTVAvL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4642 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SLYNTVAcL |
Mutations | R/V T/C |
Epitope Location | R-1V T8C |
HXB2 Location | R76V T84C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVAcL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. |
Variant ID. | 4643 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYcTVATL |
Mutations | N/C |
Epitope Location | N4C |
HXB2 Location | N80C |
Mutation Type | NSF: non-susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Note | Relative to consensus variant, SLYcTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. SLYcTVATL did not elicit an in vitro CTL response. |
Variant ID. | 4644 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYgTVATL |
Mutations | N/G |
Epitope Location | N4G |
HXB2 Location | N80G |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYgTVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4645 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYhTVATL |
Mutations | N/H |
Epitope Location | N4H |
HXB2 Location | N80H |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYhTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYhTVATL also had a reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4646 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYhlVATL |
Mutations | N/H T/L |
Epitope Location | N4H T5L |
HXB2 Location | N80H T81L |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYhlVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYhlVATL also had a reduced replicative capacity when cultured without CTLs. |
Variant ID. | 4647 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNmVATL |
Mutations | T/M |
Epitope Location | T5M |
HXB2 Location | T81M |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNmVATL had at least a 2-fold to 5-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNmVATL also had a reduced replicative capacity. |
Variant ID. | 4648 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVvTL |
Mutations | A/V |
Epitope Location | A7V |
HXB2 Location | A83V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVvTL had at least a 5-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity. |
Variant ID. | 4649 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | cLYNTVATL |
Mutations | S/C |
Epitope Location | S1C |
HXB2 Location | S77C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, cLYNTVATL had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity. |
Variant ID. | 4650 |
---|---|
Epitope Seq. | {R}SLYNTVATL{Y} |
Variant Seq. | {v}SLYNTVATL{l} |
Mutations | Y/L R/V |
Epitope Location | Y+1L R-1V |
HXB2 Location | Y86L R76V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSLYNTVATLl (-1 and +1 residues flanking SL9 epitope) had a reduced replicative capacity. |
Variant ID. | 4651 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {c}aLYNTVATL |
Mutations | R/C S/A |
Epitope Location | R-1C S1A |
HXB2 Location | R76C S77A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, caLYNTVATL (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity. |
Variant ID. | 4652 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {q}aLYNTVATL |
Mutations | R/Q S/A |
Epitope Location | R-1Q S1A |
HXB2 Location | R76Q S77A |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, qaLYNTVATL (-1 to the start of epitope SL9) had a reduced replicative capacity. |
Variant ID. | 4653 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {a}SLYNTVATv |
Mutations | R/A L/V |
Epitope Location | R-1A L9V |
HXB2 Location | R76A L85V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, aSLYNTVATv (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity. |
Variant ID. | 4654 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVAvL{m} |
Mutations | Y/M T/V |
Epitope Location | Y+1M T8V |
HXB2 Location | Y86M T84V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, SLYNTVAvLm (+1 to the end of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with SLYNTVATL-specific CTL clones. |
Variant ID. | 4655 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {v}SvYNTVATL |
Mutations | R/V L/V |
Epitope Location | R-1V L2V |
HXB2 Location | R76V L78V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Relative to consensus variant, vSvYNTVATL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vSvYNTVATL also had a substantially reduced replicative capacity. |
Variant ID. | 4854 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYgTVcTL |
Mutations | N/G A/C |
Epitope Location | N4G A7C |
HXB2 Location | N80G A83C |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, SLYgTVcTL had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgTVcTL also had a reduced replicative capacity. |
Variant ID. | 4855 |
---|---|
Epitope Seq. | SLYNTVATL{Y} |
Variant Seq. | SLYNTVATL{r} |
Mutations | Y/R |
Epitope Location | Y+1R |
HXB2 Location | Y86R |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | Other, Relative replication capacity assay |
Note | Compared to the consensus variant, SLYNTVATLr (+1 to the end of SL9 epitope) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATLr also had a substantially reduced replicative capacity. |
Gorin2017 Aleksandr M. Gorin, Yushen Du, Franklin Y. Liu, Tian-Hao Zhang, Hwee L. Ng, Christian Hofmann, William G. Cumberland, Ren Sun, and Otto O. Yang. HIV-1 Epitopes Presented by MHC Class I Types Associated with Superior Immune Containment of Viremia Have Highly Constrained Fitness Landscapes. PLoS Pathog, 13(8):e1006541, Aug 2017. PubMed ID: 28787455. Show all entries for this paper.
This is a legacy search page. It is deprecated, will receive no more updates, and will eventually be removed. Please use the new search pages.